A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines

Straeten, Aurélien vander; Sarmadi, Morteza; Daristotle, John L.; Kanelli, Maria; Tostanoski, Lisa H.; Collins, Joe; Pardeshi, Apurva; Han, Jooli; Varshney, Dhruv; Eshaghi, Behnaz; Garcia, Johnny; Forster, Timothy A.; Li, Gary; Menon, Nandita; Pyon, Sydney L.; Zhang, Linzixuan; Jacob-Dolan, Catherine; Powers, Olivia; Hall, Kevin; Alsaiari, Shahad; Wolf, Morris; Tibbitt, Mark W.; Farra, Robert; Barouch, Dan H.; Langer, Robert; Jaklenec, Ana

doi:10.1038/s41587-023-01774-z

Cited by 56 publications

(26 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ARCoV vaccine, which encodes for the SARS-CoV-2 S protein receptor-binding domain was well tolerated and immunogenic, and has the advantage of compatibility with 28C-88C storage temperatures [57]. Investigators are working to develop a microneedle patch format for thermostable COVID-19 mRNA vaccines [58]. Bottlenecks in supplies and manufacturing infrastructure need to be addressed to prevent barriers to vaccine access globally [12].…”

Section: Opportunities and Challengesmentioning

confidence: 99%

mRNA vaccines against respiratory viruses

Whitaker

Sahly

Healy

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review The successes of the coronavirus disease 2019 (COVID-19) mRNA vaccines have accelerated the development of mRNA vaccines against other respiratory pathogens. The aim of this review is to highlight COVID-19 mRNA vaccine advances and provide an update on the progress of mRNA vaccine development against other respiratory pathogens. Recent findings The COVID-19 mRNA vaccines demonstrated effectiveness in preventing severe COVID-19 and death. H7N9 and H10N8 avian influenza mRNA vaccines have demonstrated safety and immunogenicity in phase 1 clinical trials. Numerous seasonal influenza mRNA vaccines are in phase 1–3 clinical trials. Respiratory syncytial virus (RSV) mRNA vaccines have progressed to phase 2–3 clinical trials in adults and a phase 1 clinical trial in children. A combined human metapneumovirus and parainfluenza-3 mRNA vaccines was found to be well tolerated and immunogenic in a phase 1 trial among adults and trials are being conducted among children. Clinical trials of mRNA vaccines combining antigens from multiple respiratory viruses are underway. Summary The development of mRNA vaccines against respiratory viruses has progressed rapidly in recent years. Promising vaccine candidates are moving through the clinical development pathway to test their efficacy in preventing disease against respiratory viral pathogens.

show abstract

Section: Opportunities and Challengesmentioning

confidence: 99%

mRNA vaccines against respiratory viruses

Whitaker

Sahly

Healy

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…developed a printer to print microneedles. [ 195 ] The “ink” of the printer consists of a mixture of lipid nanoparticles loaded with COVID‐19 mRNA vaccines and soluble polymers (PVP: PVA), and the printed microneedles can remain stable at room temperature for six months. The invention provides conditions for the decentralized production of microneedles, and is conducive to the promotion of mRNA vaccine in areas underdeveloped or with insufficient professionals.…”

Section: Non‐invasive Administration For Improved Comfort and Enhance...mentioning

confidence: 99%

Novel Vectors and Administrations for mRNA Delivery

Bai,

Wang,

2023

Small

View full text Add to dashboard Cite

AbstractmRNA therapy has shown great potential in infectious disease vaccines, cancer immunotherapy, protein replacement therapy, gene editing, and other fields due to its central role in all life processes. However, mRNA is challenging to pass through the cell membrane due to its significant negative charges and degradation from RNase, so the key to mRNA therapy is efficient packaging and delivery of it with appropriate vectors. Presently researchers have developed various vectors such as viruses and liposomes, but these conventional vectors are now difficult to meet the growing requirement like safety, efficiency, and targeting, so many novel delivery vectors with unique advantages have emerged recently. This review mainly introduces two categories of novel vectors: biomacromolecules and inorganic nanoparticles, as well as two novel methods of control and administration based on these novel vectors: controlled‐release administration and non‐invasive administration. These novel delivery strategies have the advantages of high safety, biocompatibility, versatility, intelligence, and targeting. This paper analyzes the challenges faced by the field of mRNA delivery in depth, and discusses how to use the characteristics of novel vectors and administrations to solve these problems.

show abstract

“…2 Microneedles (MNs), painless and active transdermal delivery devices, have been widely investigated and applied for cancer treatment, vaccination, and wound healing by transporting molecules with a molecular weight larger than 500 Dalton. 3–5 MNs can be categorized into hollow microneedles, coated microneedles, hydrogel microneedles, and dissolving microneedles based on the matrix materials and mechanisms. 6–9 However, most of them require complicated fabrication procedures or have limited drug-loading capacities.…”

Section: Introductionmentioning

confidence: 99%